Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2025-09-26 00:00:00 ET · period of report 2025-09-25 · accession 0001856369-25-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-09-26 | 2025-09-25 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +100.0K | 1.05M | +10% | $0 |
| D | 2025-09-26 | 2025-09-25 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $4.76 | -100.0K | 954.2K | -9% | -$476.0K |
| D | 2025-09-26 | 2025-09-25 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | — | 0 | 5.25M | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2025-09-25 | C | A | 100,000 | $0.00 | 1,054,229 | D | — | — | |
| 2 | Common | Class A Common Stock | 2025-09-25 | S | D | 100,000 | $4.76 | 954,229 | D | — | — | |
| 3 | Derivative | Class B Common Stock | 2025-09-25 | C | D | 0 | $0.00 | 5,253,034 | D | $0.00 · — to — | 100,000 Class A Common Stock | (F1) Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. |